



## NOXOPHARM CORPORATE PRESENTATION

**Sydney 7 June 2022:** Australian biotech **Noxopharm Limited (ASX:NOX)** is pleased to provide a corporate slide deck ahead of a series of non-deal investor meetings. The release is accompanied by a recorded presentation by the recently appointed CEO and Managing Director, Dr Gisela Mautner and will be available on the Noxopharm website.

In the presentation, Dr Gisela Mautner:

- provides a personal introduction and discusses Noxopharm's key priorities, business model, global high-calibre network of collaborators, and pathway to the future
- outlines Noxopharm's current active Clinical Trial program with Veyonda®
- discusses Noxopharm's two innovative technology platforms: Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity)

A copy of the corporate slide deck is attached. To access Dr Mautner's recording, please visit <https://investor.noxopharm.com/site/investors/presentations/noxopharm-new-corporate-presentation-june-2022> or you will find it on the Noxopharm website under 'Presentations & Interviews'.

**-ENDS-**

---

### About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its lead clinical-stage drug candidate Veyonda®, plus two innovative technology platforms – Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

# **NOXOPHARM LIMITED**

**Delivering Science. Transforming Lives.**

# Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction.

It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors (including but not limited to the COVID-19 pandemic) many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Veyonda® currently is not approved for use in Australia or any other country.




Noxopharm

Committed to developing  
life-saving therapies

# Noxopharm Overview

- **Noxopharm is an innovative biotechnology company with a science driven strategy** to advance the most promising life-saving therapies for patients with cancer or inflammatory diseases
- It has grown to have **three separate drug development programs**:
  - Lead clinical-stage drug candidate **Veyonda®**
  - **Chroma™** technology platform
  - **Sofra™** technology platform
- **Multiple Phase 1 and 2 studies** running in a range of cancer types including prostate, breast and lung cancer as well as sarcoma
- **Well-funded** for current programs with \$18.1 million cash\*
- Expert team, highly experienced at identifying and driving novel drugs from **molecule to marketplace** while **adding value** at each step



\* As at 31 March 2022



# Highly Qualified and Experienced Management Team



Left to right: CSO (Oncology) Dr John Wilkinson, CSO (Inflammation and Autoimmunity) Dr Olivier Laczka, CEO & Managing Director Dr Gisela Mautner, COO Dr Jeanette Bell, CFO Shawn van Boheemen.

## Chief Executive Officer and Managing Director

**Dr Gisela Mautner** MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), MAICD

- Over 30 years' experience in healthcare across four continents with leadership roles in Global Pharmaceuticals including Operational, Medical and Scientific Advisory, Research and Marketing roles in multiple therapeutic areas

## Chief Operating Officer

**Dr Jeanette Bell** BMedSc, MScM, PhD

- Over 30 years' experience in multinational pharmaceuticals and local healthcare settings; with leadership roles in Medical and Commercial Operations, Drug Development, Clinical Research, Medical Affairs, Sales, Marketing and Launch Excellence

## Chief Scientific Officer (Oncology)

**Dr John Wilkinson** PhD, BSc

- Over 30 years of experience from biotech, pharmaceutical and research settings, with a strong track record in Oncology, Virology, Drug Development, Manufacturing, Regulatory, Pre-clinical and Clinical Research

## Chief Scientific Officer (Inflammation & Autoimmunity)

**Dr Olivier Laczka** BSc, MSc, PhD

- 20 years' scientific and corporate experience in Australian biotech companies and global academic settings conducting multidisciplinary research projects, attracting external research funding with private entities and government organizations

## Chief Financial Officer

**Shawn van Boheemen** BBus, MCom, FCPA, JP

- Over 30 years' commercial finance experience encompassing Manufacturing, Contract Research, Medical Devices, Biotech and Financial Services across a mix of local and multinational organisations

# The Noxopharm Network



**Goethe  
Universität**  
Frankfurt Am Main

**Hudson  
Institute of  
Medical Research**  
Melbourne

**NIH**  
National Institutes  
of Health  
USA

**NCI**  
National Cancer  
Institute  
USA

**Weill Cornell  
Medicine**  
New York

**Australian  
National  
University**  
Canberra

**The University of  
Queensland**  
Brisbane

**University of New  
South Wales**  
Sydney

**University of  
South Australia**  
Adelaide


**University of  
Technology**  
Sydney



# Value Cascade


Noxopharm's **science driven strategy** is to advance the most promising life-saving therapies through the discovery, preclinical and clinical phases.

Its focus is on **adding value to its assets** at each step of the value cascade.



# The Noxopharm Business Model

Proprietary and in-licensed drugs are advanced through drug development, with a view to out-licensing them at key value inflection points.



# Three Separate Therapy Development Programs

Lead Candidate



Veyonda<sup>®</sup>

Clinical Phase 1 / 2 Trials

Innovative Technology Platforms



Chroma<sup>™</sup>

Preclinical Studies



Sofra<sup>™</sup>



# Veyonda<sup>®</sup> Combination Therapy Programs

**DARRT**




External Beam Radiation

**CEP**



Chemotherapy

**IONIC (IIT\*)**








Immuno-oncology Therapy

Working with top ranked cancer centres in the USA

\* IIT – investigator initiated trial



# Veyonda<sup>®</sup> Clinical Development

Program	Combination	Indication	Phase 1	Phase 2	Status
<b>DARRT</b>	 + Radiation Therapy	Prostate Cancer	<b>DARRT-1 Completed</b>	<b>DARRT-2 Active</b>	DARRT-1 manuscript in preparation; DARRT-2 recruiting
<b>CEP</b>	 + Chemotherapy	Multiple Tumours	<b>CEP-1 Completed</b>		Results published in CTR 2021
		Sarcoma	<b>CEP-2 Active</b>		Recruitment ongoing
<b>IONIC (IIT)*</b>	 + Immunotherapy (Opdivo <sup>®</sup> ) †	Multiple Tumours	<b>IONIC Active</b>		Recruitment ongoing
<b>LuPIN (IIT)*</b>	 + <sup>177</sup> LuPSMA-617 (Pluvicto <sup>®</sup> ) ‡	Prostate Cancer	<b>LuPIN Completed</b>		Results published in JNM in 2022
<b>NOXCOVID</b>	 Monotherapy	COVID-19	<b>NOXCOVID Completed</b>		Manuscript in preparation

\* IIT - investigator initiated trial

† Bristol Myers Squibb

‡ Novartis



# Regulatory Engagement for Veyonda®

## Orphan Drug Designation (ODD)

- US Food and Drug Administration (FDA) granted ODD to Veyonda for soft tissue sarcoma – early 2022
  - Supports Veyonda’s development in sarcoma via the **CEP-2** trial
- Only four Australian companies received ODD approval in 2021

## Regulatory trial approvals

- US FDA Investigational New Drug (IND) granted for Veyonda in combination with doxorubicin for the treatment of sarcoma – CEP-2 trial
- US FDA IND granted for investigation of Veyonda in prostate cancer – DARRT-2 trial
- Approvals followed regulatory evaluation of significant Veyonda data packages
- Enabled CEP-2 and DARRT-2 trials to take place in these important commercial territories
- Trial sites in Australia, the United States and Europe

## Highly Valuable ODD Benefits

ODD encourages the development of safe and effective treatments of rare diseases affecting fewer than 200,000 people in the U.S. annually.

Seven-year period of market exclusivity

Waiver of new drug application fees, valued at approximately \$2.9 million in 2021

Regulatory guidance and assistance from the FDA for drug development



# Innovation is Needed in Prostate Cancer

Prostate cancer is one of the most common cancers in men.

## Poor outlook in advanced cases<sup>1</sup>

- Current treatments slow or shrink an advanced prostate cancer, but for most men, stage 4 prostate cancer is not curable
- Radiation therapy is a widely used standard-of-care treatment; in the palliative setting it can only reduce symptoms, but will not increase life span
- Innovation is needed to decrease tumour size and spread; this will reduce pain, improve quality of life and increase lifespan

In 2022 in the US, there will be an estimated **268,490** new prostate cancer cases and **34,500** deaths<sup>2</sup>

Globally, more than 1.4 million new prostate cancer cases were diagnosed in 2020<sup>3</sup>

Prostate cancer is the most frequently diagnosed cancer in 112 countries, and the leading cause of cancer death in 48 countries<sup>3</sup>

<sup>1</sup> <https://www.juneoclinic.org/diseases-conditions/stage-4-prostate-cancer/diagnosis-treatment/drc-20377972>

<sup>2</sup> [https://cancerstatisticscenter.cancer.org/?\\_ga=2.20651128.1373134204.1652941019-127656175.1652763585#!/cancer-site/Prostate](https://cancerstatisticscenter.cancer.org/?_ga=2.20651128.1373134204.1652941019-127656175.1652763585#!/cancer-site/Prostate)

<sup>3</sup> Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., & Du, L. (2022). Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. *Frontiers In Public Health*, 10. doi: 10.3389/fpubh.2022.811044

# Unmet Medical Need in Sarcoma

Soft tissue sarcomas are rare but often fatal cancers.

## Limited treatment options

- Surgery, chemotherapy and/or radiotherapy are all existing treatment options
- Standard-of-care treatment for metastatic soft tissue sarcoma remains **doxorubicin** chemotherapy
- However, patient outcomes have not improved significantly over the last few decades

New sarcoma treatments are eligible to apply for Orphan Drug Designation from the US FDA

In the US each year, up to **16,000** new sarcoma cases are diagnosed, and up to **6,000** related deaths are recorded<sup>1</sup>

Sarcoma is among the **top 5** causes of cancer deaths for those aged under 20 years of age<sup>1</sup>.

Up to **50%** of high-grade sarcoma patients develop metastases and die within 12 months

<sup>1</sup> Gage MM, Nagarajan N, Ruck JM, et al. Sarcomas in the United States: Recent trends and a call for improved staging. *Oncotarget*. 2019;10(25):2462-2474. 2019 Mar 29. doi: [10.18632/oncotarget.26809](https://doi.org/10.18632/oncotarget.26809)

# Scientific Validation of Trial Results

Phase Ib/IIa Study of NOX66 in Combination with Radiotherapy in Patients with Late-Stage Metastatic Castration-Resistant Prostate Cancer (DARRT-1 Study)  
 Paul L. de Souza<sup>1</sup>, Arno Capp<sup>2</sup>, Nana Chikhladze<sup>3</sup>, Tamar Melkadze<sup>4</sup>, Marina Messina<sup>5</sup>, Greta Mautner<sup>6</sup>  
 available at [www.sciencedirect.com](http://www.sciencedirect.com)  
 journal homepage: [euoncolology.europeanurology.com](http://euoncolology.europeanurology.com)

EUROPEAN UROLOGY ONCOLOGY 4 (2021) 963-970  
 European Association of Urology

FEATURED ARTICLE OF THE MONTH  
**177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial**  
 Sarenya Pathmanandavel<sup>1,3</sup>, Megan Crumbaker<sup>2,4</sup>, Andrew O. Yam<sup>2,4</sup>, Andrew Nguyen<sup>1</sup>, Christopher Rotte<sup>2</sup>, Elizabeth Hovey<sup>5,6</sup>, Craig Gedye<sup>5,6</sup>, Edmond M. Kwan<sup>5,6</sup>, Christine Hauser<sup>1,12</sup>, Arun A. Azad<sup>1</sup>, Peter Eu<sup>1,1,3,4,6</sup>, Andrew J. Martin<sup>1,3</sup>, Anthony M. Joshua<sup>2,4,6</sup>, and Louise Emmett<sup>1,3,4,6</sup>

Phase I/II Trial of the Combination of <sup>177</sup>Lutetium Prostate-Specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer  
 Megan Crumbaker<sup>1,3</sup>, Sarenya Pathmanandavel<sup>1,3</sup>, Andrew O. Yam<sup>2,4</sup>, Andrew Nguyen<sup>1</sup>, Christopher Rotte<sup>2</sup>, Elizabeth Hovey<sup>5,6</sup>, Craig Gedye<sup>5,6</sup>, Edmond M. Kwan<sup>5,6</sup>, Christine Hauser<sup>1,12</sup>, Arun A. Azad<sup>1</sup>, Peter Eu<sup>1,1,3,4,6</sup>, Andrew J. Martin<sup>1,3</sup>, Anthony M. Joshua<sup>2,4,6</sup>, and Louise Emmett<sup>1,3,4,6</sup>

Abstract #103: Final results of a phase III trial of the combination of <sup>177</sup>Lutetium PSMA 617 and Idronoxil (NOX66)  
 Megan Crumbaker<sup>1,3</sup>, Sarenya Pathmanandavel<sup>1,3</sup>, Andrew O. Yam<sup>2,4</sup>, Andrew Nguyen<sup>1</sup>, Christopher Rotte<sup>2</sup>, Elizabeth Hovey<sup>5,6</sup>, Craig Gedye<sup>5,6</sup>, Edmond M. Kwan<sup>5,6</sup>, Christine Hauser<sup>1,12</sup>, Arun A. Azad<sup>1</sup>, Peter Eu<sup>1,1,3,4,6</sup>, Andrew J. Martin<sup>1,3</sup>, Anthony M. Joshua<sup>2,4,6</sup>, and Louise Emmett<sup>1,3,4,6</sup>

Background: Prostate-specific membrane antigen (PSMA) is a novel target for prostate cancer treatment. <sup>177</sup>Lutetium-PSMA-617 (<sup>177</sup>Lu-PSMA-617) has shown good efficacy and safety in phase I/II trials. Idronoxil (NOX66) is a novel androgen receptor inhibitor that shows promising activity in phase I trials. The combination of <sup>177</sup>Lu-PSMA-617 and NOX66 may improve treatment response in men with end-stage metastatic castration-resistant prostate cancer (mCRPC).

Methods: In this phase III trial, 300 men with mCRPC were randomized to receive either <sup>177</sup>Lu-PSMA-617 (n=150) or <sup>177</sup>Lu-PSMA-617 plus NOX66 (n=150). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), PSA response rate, and quality of life.


Results: The median OS was 10.7 months (95% CI 9.5-12.0) in the <sup>177</sup>Lu-PSMA-617 group and 10.9 months (95% CI 9.5-12.3) in the combination group. The PSA response rate was significantly higher in the combination group (60.0% vs 45.0%, p=0.002).

Conclusions: The combination of <sup>177</sup>Lu-PSMA-617 and NOX66 shows promising activity in men with mCRPC. Further studies are warranted to evaluate the long-term efficacy and safety of this combination.

NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study  
 Koba Kiknavelidze, PhD<sup>1</sup>, Mikheil Shavdia, PhD<sup>2</sup>, Nana Chikhladze, PhD<sup>3</sup>, Lia Abshilava, PhD<sup>4</sup>, Marinella Messina, PhD<sup>5</sup>, Gisela Mautner, MD, PhD<sup>5,6</sup>, Graham Kelly, PhD<sup>5</sup>

Peer-reviewed publications of key results validate the science behind Noxopharm's drug candidates

# Innovative Technology Platforms – Preclinical Stage





# Chroma™

- ✓ Shared specific and novel bioactive properties
- ✓ Growing number of drug assets
- ✓ Deepening knowledge of structural /activity relationships
- ✓ Composition of Matter patents
- ✓ Promising early results in pancreatic cancer

## Pancreatic ductal adenocarcinoma (PDAC)

- PDAC is the **fourth leading cause of cancer**-related deaths in developed countries
- 5-year survival rate of **8%** from diagnosis<sup>1</sup>, minimal improvements in the past four decades
- In 2018, approximately **458,918 people** were diagnosed with pancreatic cancer, while 432,242 died<sup>2</sup>
- Chemotherapy treatments only extend life by 8-16 weeks<sup>3</sup>
- Pancreatic cancer is eligible for Orphan Drug Designation

**Urgent need to develop more effective treatments**

<sup>1</sup> Siegel RL. 2018. doi:10.3322/caac.21442.


<sup>2</sup> Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. \.

<sup>3</sup> Kleeff J. 2016. doi:10.1038/nrdp.2016.22





# Novel 'Dual-Cell' Therapy for Pancreatic Cancer



***Growing Tumour Shielded by a 'Wall' of Scar Tissue***      ***'Dual-Cell' Therapy of CRO-XX through 1) Penetration of the 'Wall' and Opening the Gates to Immune Cells plus 2) direct Tumour Cell Killing by CRO-XX***





Sofra™


pharmorage



### Nature

RNA / DNA

Oligonucleotides



### Proprietary Technology

Chemically engineered oligonucleotides



- Over 200 synthetic sequences
- Composition of Matter patents
- Targeting inflammatory and autoimmune diseases
- Novel treatment approach

**First-in-class drug candidates**

# Financial Summary (ASX:NOX)


## Capital Structure

Share price <sup>1</sup>	\$0.315
Shares on issue	292M
Market Capitalisation <sup>1</sup>	\$92M
Net capital raised <sup>2</sup>	\$63.8M
Govt grants/rebates received <sup>3</sup>	\$18.5M





## Cash Position

Current Cash Holdings <sup>4</sup>	\$18.1M
Average Cash burn/mth	\$1.9M
Est R&D rebate for 2021/22 <sup>5</sup>	\$5-6M

# 2022 Catalysts



# Integrating Environment, Social and Governance (ESG) into Everyday Practice

	<p><b>Supply Chains</b></p>	<p>We will seek greater insight into the sustainability practices of our supply chain vendors to ensure transparency across the manufacture and supply chain.</p>
	<p><b>Investor Relations</b></p>	<p>We will strive to align ESG best practice with investor expectations to broaden Noxopharm’s shareholder base, attract investment from the sustainable investment community, and ensure financial longevity.</p>
	<p><b>Roadshows</b></p>	<p>We will communicate our ESG roadmap development to current and potential investors as the company grows. We intend to effectively manage ESG sustainability related risks through transparent risk mitigation practices.</p>
	<p><b>Company Culture</b></p>	<p>We will continue to align and integrate ESG practices into our company culture to build a socially and commercially sustainable future for Noxopharm and our stakeholders.</p>

# Investment Highlights

Three exciting drug development programs focused on cancer and inflammatory diseases

**Veyonda<sup>®</sup>,  
Chroma<sup>™</sup> &  
Sofra<sup>™</sup>**

Science-driven strategy to advance drugs to key value inflection points, before out-licensing to optimise value for shareholders

**Value Creation**

Expert management team & network of leading medical research collaborators in Australia, USA and Europe

**Experts**

Multiple clinical data catalysts ahead, plus advancements from preclinical platforms

**News Flow**

Well funded with cash runway beyond multiple value creating milestones

**Well Funded**

# **NOXOPHARM LIMITED**

**Delivering Science. Transforming Lives.**

[www.noxopharm.com](http://www.noxopharm.com)

